C&D completes acquision of Del OTC business
PRINCETON, N.J. Church & Dwight on Monday completed its previously announced acquisition of the Del OTC pharmaceutical business from Coty.
The transaction was completed substantially under the original terms announced April 1, which called for Church & Dwight to pay $380 million in cash at closing.
“The Orajel brand will be a great addition to the Church & Dwight family,” reiterated James Craigie, chairman and chief executive officer. “We are excited to expand our personal care portfolio and strengthen our presence in the strategic oral care category.”
Report says early nutrition could affect child’s later health
LONDON A report published in The Journal of Physiology and released by a group of British researchers stated that women who do not follow healthy diets during pregnancy might see higher risk level for their children to face elevated cholesterol and blood sugar levels, and obesity.
The Royal Veterinary College, working with a group of rats, experimented feeding one group of females only processed foods like chips, cookies, donuts and other sweets while they were pregnant and nursing. Another test group of female rats got a diet of regular feed.
After a prolonged diet, the female rats and their offspring were compared. Researchers said the offspring of the rats that were fed a junk food diet had higher levels of cholesterol and triglycerides, two agents known to cause cancer, in their blood. They also had higher levels of glucose and insulin, which are tied to heightened risks of Type 2 diabetes. The rats given the junk food diet remained fatter through adolescence and into adulthood.
Professor Neil Stickland said that even though this study and all if its implications were conduced exclusively on rats, the findings could probably be attributed to humans as well.
Court rules against Abbott in glucose-testing case
SAN FRANCISCO Bayer AG has won a court ruling that states a patent used by Abbott Laboratories in glucose-testing products isn’t enforceable because a company attorney used misrepresentations to get the patent approved, according to published reports.
Lawrence Pope, formerly an attorney at Abbott Labs, acted with “specific intent to deceive” the patent examiner, U.S. District Judge William Alsup in San Francisco said in his ruling. Pope withheld information that would have hurt Abbott’s case, Alsup wrote in the 54-page ruling.
“Intent to deceive, not just withhold, was clearly in the mind of” Pope, the judge wrote. “If concealment of extrinsic information as close to the heart of the prosecution as was involved here is allowed to pass, then we would in effect be issuing licenses to deceive patent examiners in virtually all cases.”
Abbott first sued Bayer in 2005 claiming patent infringement seeking unspecified damage. Abbott claimed test strips in two Bayer glucose-testing products that are no longer on the market infringed three Abbott patents.
Abbott maintains the patent was “obtained lawfully,” and is weighing its legal options, said spokesman Scott Stoffel. “Abbott continues to believe that this patent is valid and enforceable and that the defendants’ products infringe.”